12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Company News  |  Deals

Symplmed, Xoma deal

Symplmed acquired from Xoma exclusive, U.S. rights to develop and commercialize a fixed-dose combination of perindopril/amlodipine and a sublicense to promote Aceon perindopril erbumine in the U.S. Xoma will receive an undisclosed equity stake in Symplmed and is eligible for up to double-digit royalties on...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >